Emerging concepts in optimizing antimicrobial therapy of septic shock: Speed is life but a hammer helps too

Critical Care

Volumn 17, Issue 1, 2013, Pages

  Kumar, Anand ^a   Kethireddy, Shravan ^b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b GEISINGER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; ANTIBIOTIC AGENT; BETA LACTAM; CEFTAZIDIME; CEPHALOSPORIN; CLINDAMYCIN; CLOXACILLIN; MACROLIDE; MEROPENEM; MOXIFLOXACIN; OXACILLIN; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TICARCILLIN; TIMENTIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; CRITICALLY ILL PATIENT; DEATH; DRUG POTENCY; HEMODYNAMICS; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NONHUMAN; NOTE; PRIORITY JOURNAL; PSEUDOMONAS; SEPSIS; SEPTIC SHOCK; SURVIVAL; CLINICAL PRACTICE; FEMALE; MALE; STATISTICS AND NUMERICAL DATA;

ANTI-BACTERIAL AGENTS; FEMALE; HUMANS; MALE; PHYSICIAN'S PRACTICE PATTERNS; SEPSIS;

EID: 84872403125     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc11890     Document Type: Note

References (8)

1. Diaz-Martin A, Martinez-Gonzalez ML, Ferrer R, Ortiz-Leyba C, Piacentini E, Lopez-Pueyo MJ, Martin-Loeches I, Levy MM, Artigas A, Garnacho-Montero J, . the Edusepsis Study Group Antibiotic prescription patterns in the empirical therapy of severe sepsis: combination of antimicrobials with different mechanisms of action reduce mortality. Crit Care 2012, 16:R223. 10.1186/cc11869, 23158399, the Edusepsis Study Group.
2. Suffredini AF, Munford RS. Novel therapies for septic shock over the past 4 decades. JAMA 2011, 306:194-199. 10.1001/jama.2011.909, 21750297.
3. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut JF, Gerlach H, Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson BT, Townsend S, Vender JS, Zimmerman JL, Vincent JL. Surviving Sepsis Campaign: international guidelines for managment of severe sepsis and septic shock. Intensive Care Med 2008, 34:17-60. 10.1007/s00134-007-0934-2, 2249616, 18058085.
4. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Kumar A, Cheang M. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006, 34:1589-1596. 10.1097/01.CCM.0000217961.75225.E9, 16625125.
5. Kumar A, Zarychanski R, Light B, Parrillo J, Maki D, Simon D, Laporta D, Lapinsky S, Ellis P, Mirzanejad Y, Martinka G, Keenan S, Wood G, Arabi Y, Feinstein D, Kumar A, Dodek P, Kravetsky L, Doucette S, . Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database Research Group Early combination antibiotic therapy yields improved survival compare with monotherapy in septic shock: a propensity-matched analysis. Crit Care Med 2010, 38:1773-1785. 10.1097/CCM.0b013e3181eb3ccd, 20639750, Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database Research Group.
6. Kumar A, Safdar N, Kethireddy S, Chateau D. A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: a metaanalytic/meta-regression study. Crit Care Med 2010, 38:1651-1664. 10.1097/CCM.0b013e3181e96b91, 20562695.
7. Brunkhorst FM, Oppert M, Marx G, Bloos F, Ludewig K, Putensen C, Nierhaus A, Jaschinski U, Meier-Hellmann A, Weyland A, Gründling M, Moerer O, Riessen R, Seibel A, Ragaller M, Büchler MW, John S, Bach F, Spies C, Reill L, Fritz H, Kiehntopf M, Kuhnt E, Bogatsch H, Engel C, Loeffler M, Kollef MH, Reinhart K, Welte T, . German Study Group Competence Network Sepsis (SepNet) Effect of empirical treatment with moxifloxacin and meropenam vs meropenam on sepsis-related organ dysfunction in patients with severe sepsis. JAMA 2012, 307:2390-2399. German Study Group Competence Network Sepsis (SepNet).
8. Craig WA. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998, 16:1-10.